Geometric Mean Fold-rise (GMFR) of Serum Neutralization Antibody Titers at Day 22;Geometric Mean Fold-rise of Serum Neutralization Antibody Titers at Day 36;Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine Formulations at Day 1;Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine Formulations at Day 22;Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine Formulations at Day 36;Number of Participants With >=2-Fold and >=4-Fold Rise in Serum Neutralization Antibody Titer at Day 36;Number of Participants With >=2-fold and >=4-fold Rise in Serum Neutralization Antibody Titers at Day 22;Number of Participants With Adverse Events of Special Interest (AESIs);Number of Participants With Immediate Unsolicited Adverse Events (AEs);Number of Participants With Laboratory Test Results Based on US FDA Toxicity Grading Guidance;Number of Participants With Medically Attended Adverse Events (MAAE);Number of Participants With Serious Adverse Events (SAE);Number of Participants With Solicited Injection Site Reactions;Number of Participants With Solicited Systemic Reactions;Number of Participants With Unsolicited Adverse Events;Percentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens at Day 22;Percentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens at Day 36

Geometric Mean Fold-rise (GMFR) of Serum Neutralization Antibody Titers at Day 22;Geometric Mean Fold-rise of Serum Neutralization Antibody Titers at Day 36;Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine Formulations at Day 1;Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine Formulations at Day 22;Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine Formulations at Day 36;Number of Participants With >=2-Fold and >=4-Fold Rise in Serum Neutralization Antibody Titer at Day 36;Number of Participants With >=2-fold and >=4-fold Rise in Serum Neutralization Antibody Titers at Day 22;Number of Participants With Adverse Events of Special Interest (AESIs);Number of Participants With Immediate Unsolicited Adverse Events (AEs);Number of Participants With Laboratory Test Results Based on US FDA Toxicity Grading Guidance;Number of Participants With Medically Attended Adverse Events (MAAE);Number of Participants With Serious Adverse Events (SAE);Number of Participants With Solicited Injection Site Reactions;Number of Participants With Solicited Systemic Reactions;Number of Participants With Unsolicited Adverse Events;Percentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens at Day 22;Percentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens at Day 36

Number of Participants with Unsolicited Adverse Events;Number of Participants with Serious Adverse Events (SAEs);2-fold and 4-fold Rise in Neutralization Antibody titer at Day 36;Percentage of Participants with Neutralizing Antibody Seroconversion at Day 36;Percentage of Participants with Neutralizing Antibody Seroconversion at Day 22;Number of Participants with Immediate Adverse Events;2-fold and 4-fold Rise in Neutralization Antibody titer at Day 22;Number of Participants With Solicited Injection Site or Systemic Reactions;Number of Participants with Out-of-range Biological Test Results;Neutralizing Antibody Titer at Day 22;Fold-rise of Neutralizing Antibody Titer at Day 36;Number of Participants with Adverse Events of Special Interest;Neutralizing Antibody Titer at Day 1;Fold-rise of Neutralizing Antibody Titer at Day 22;Number of Participants with Medically Attended Adverse Events;Neutralizing Antibody Titer at Day 36

Number of Participants with Unsolicited Adverse Events;Number of Participants with Serious Adverse Events (SAEs);2-fold and 4-fold Rise in Neutralization Antibody titer at Day 36;Percentage of Participants with Neutralizing Antibody Seroconversion at Day 36;Percentage of Participants with Neutralizing Antibody Seroconversion at Day 22;Number of Participants with Immediate Adverse Events;2-fold and 4-fold Rise in Neutralization Antibody titer at Day 22;Number of Participants With Solicited Injection Site or Systemic Reactions;Number of Participants with Out-of-range Biological Test Results;Neutralizing Antibody Titer at Day 22;Fold-rise of Neutralizing Antibody Titer at Day 36;Number of Participants with Adverse Events of Special Interest;Neutralizing Antibody Titer at Day 1;Fold-rise of Neutralizing Antibody Titer at Day 22;Number of Participants with Medically Attended Adverse Events;Neutralizing Antibody Titer at Day 36